Robeco Institutional Asset Management B.V. bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 8,151 shares of the specialty pharmaceutical company's stock, valued at approximately $267,000.
A number of other institutional investors have also added to or reduced their stakes in SUPN. Raiffeisen Bank International AG acquired a new position in Supernus Pharmaceuticals during the fourth quarter worth $25,000. Financial Management Professionals Inc. bought a new position in Supernus Pharmaceuticals during the first quarter worth $30,000. Versant Capital Management Inc boosted its position in Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock worth $37,000 after purchasing an additional 1,109 shares during the period. GF Fund Management CO. LTD. bought a new position in Supernus Pharmaceuticals during the fourth quarter worth $42,000. Finally, Smartleaf Asset Management LLC boosted its position in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after purchasing an additional 870 shares during the period.
Analysts Set New Price Targets
Separately, Wall Street Zen cut shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, June 21st.
Check Out Our Latest Research Report on Supernus Pharmaceuticals
Supernus Pharmaceuticals Price Performance
SUPN stock opened at $32.07 on Thursday. The company has a fifty day moving average price of $32.25 and a two-hundred day moving average price of $33.92. Supernus Pharmaceuticals, Inc. has a one year low of $25.55 and a one year high of $40.28. The stock has a market cap of $1.80 billion, a price-to-earnings ratio of 28.89 and a beta of 0.70.
About Supernus Pharmaceuticals
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
See Also
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
